Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

Inclusion Criteria: * The subject must sign the informed consent form. * Aged 18 to 70 years inclusive, no gender restriction. * Subjects with definite diagnosis of Crohn's disease in accordance with Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023), presenting moderate to severe active Crohn's disease with inadequate response, intolerance or contraindication to adequate glucocorticoid and/or immunosuppressant therapy. * Adult patients with Crohn's disease who are prescribed Tabellvi® Adalimumab Injection by physicians following thorough risk-benefit assessment. * Female subjects of childbearing potential must agree to use one contraceptive method approved by the investigator. Exclusion Criteria: * Subjects who are not suitable for treatment with Tabellvi® Adalimumab Injection based on the prescribing information of Tabellvi® Adalimumab Injection and the judgment of the treating physician. * Female subjects who are pregnant or breastfeeding, or who plan to become pregnant during the study period. * Subjects with hypersensitivity to any component of Tabellvi® Adalimumab Injection. * Subjects with active, chronic or recurrent infections, or a medical history of invasive infections (e.g., listeriosis, histoplasmosis). * Subjects with active infections requiring intravenous anti-infective therapy within 30 days prior to the first dose, or those who have received oral anti-infective drugs within 14 days prior to the first dose. * Subjects w…